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Several studies during the past 15 years have 
shown that antihypertensive therapy with different 
types of drugs can reduce microalbuminuria or 
clinical proteinuria and retard the progression to­
ward end-stage renal failure. However, some au­
thors reported disparate renal protective effects of 
different antihypertensive drugs in diabetic ani­
mals and humans. In an attempt to resolve the 
controversy surrounding this possibility, previ­
ously we reported a meta-analysis of published 
studies in diabetics with microalbuminuria or 
overt proteinuria treated with conventional agents, 
angiotensin-converting enzyme (ACE) inhibitors, 
or calcium antagonists ( C a 2 + antagonists). Here we 
present an updated meta-analysis of published 
studies in diabetics with microalbuminuria or clin­
ical proteinuria (UProt), treated during > 4 weeks 
with ACE inhibitors, C a 2 + antagonists, or conven­
tional therapy (diuretic and/or β-blocker). Despite 
similar blood pressure (BP) reductions, UProt 
tended to decrease more on ACE inhibitors (on av­
erage - 4 5 % ) than on conventional therapy (on av­
erage - 2 3 % ) or C a 2 + antagonists other than nifed­
ipine (on average —35%); in contrast, UProt tended 
to increase slightly on nifedipine (on average 5%, 
Ρ < .05). On the basis of multiple regression anal­
ysis, ACE inhibitor-induced UProt changes corre­
lated with BP changes (r = 0.77, Ρ < .00001), aver­
aged - 2 8 % at zero BP change, and varied 1.5% for 
each percent BP change. On conventional therapy, 
UProt and BP changes also correlated (r = 0.62, Ρ 
< .005), but UProt began to decrease only after a 
BP reduction of > 5 % and the slope was steeper 
(4% UProt change per percent BP change) than on 
ACE inhibitors. On C a 2 + antagonists other than 
nifedipine, UProt was unchanged at zero BP 
change, and the regression line for the relationship 
between changes in UProt (r = 0.55, Ρ < .05) was 
in an intermediate position between ACE inhibi­
tors and conventional treatment. Seventy reports 
also contained data on glomerular filtration rate 
(GFR). On ACE inhibitors, GFR was on average 
unchanged, but tended to increase slighty with 
progressive BP reduction (r = - 0 . 5 5 , Ρ < .0001). 
On conventional therapy or Ca 2 + .antagonists, vari­
ations in GFR were unrelated to changes in BP. 
As ACE inhibitors exert a specific antiproteinuric 
effect even without a change in systemic BP, they 
are superior to other agents in treating microalbu­
minuria or overt proteinuria in initially normoten­
sive or mildly hypertensive diabetic patients. On 
the other hand, when systemic BP can be lowered 
by 20%, as it is desirable in severely hypertensive 
patients, ACE inhibitors, conventional therapy, 
and several C a 2 + antagonists all have a distinct an­
tiproteinuric action. In contrast, as the example of 
nifedipine illustrates, drug-specific intrarenal ef­
fects may antagonize a BP-dependent antiproteinu­
ric action and even counteract the effect of lower­
ing systemic pressure. It is of note that ACE inhib­
itors may, in addition to their antiproteinuric effect, 
exert a drug-specific beneficial influence on GFR. 
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The incidence and prevalence of renal failure secondary to diabetes mellitus has increased steadily during the past decade in the United States 1; therefore, diabetes is now the lead­
ing cause of end-stage renal disease. 2 Microalbumin­
uria (30 to 300 mg/24 h) predicts overt nephropathy 
(proteinuria > 3 0 0 mg/24 h) and chronic renal failure 
in diabetic individuals.3 It has also a powerful asso­
ciation with macrovascular disease, which is unex­
plained by simultaneous existing cardiovascular risk 
factors. 4 
Among the 35% of patients with insulin-dependent 
diabetes mellitus (IDDM) who will develop nephrop­
athy, persistent microalbuminuria ("incipient ne­
phropathy") appears 5 to 10 years after the onset of 
diabetes. It usually progresses to the stages of overt 
nephropathy and later on to end-stage renal fail­
u r e . 5 , 6 Hypertension contributes to the progression of 
diabetic nephropathy in IDDM. 7 Blood pressure (BP) 
is usually normal in the absence of nephropathy, 
tends to rise before or concomitantly with the onset of 
incipient nephropathy, and increases further when 
renal damage progresses to the stages of clinical ne­
phropathy and renal fai lure . 5 , 8 , 9 In patients with 
non-insulin-dependent diabetes mellitus (NIDDM), 
the temporal relationship between the onset of hy­
pertension and nephropathy, respectively, is more 
variable; hypertension most often precedes and 
sometimes follows diabetes. On the one hand, pro­
gression of nephropathy aggravates hyperten­
s i o n , 1 0 , 1 1 but on the other hand once nephropathy is 
present, a high BP may also promote and accelerate 
the development of renal failure. 1 0 Compared with 
the general population, relative mortality from car­
diovascular disease is increased about fivefold in di­
abetics with hypertension 1 2 , 1 3 and about 35-fold in 
diabetics with clinical nephropathy. 7 , 1 4 
Attempts at slowing progression of overt diabetic 
nephropathy have included dietary modifications 
and antihypertensive therapy. Severe restriction of 
protein intake may slightly retard progression to re­
nal failure, 1 5 but the feasibility and acceptability of 
this dietary modification are even more problematic 
in diabetic than in nondiabetic patients. Several stud­
ies during the past 15 years have shown that antihy­
pertensive therapy with different types of drugs can 
reduce microalbuminuria or clinical proteinuria and 
retard the progression toward end-stage renal fail­
u r e . 5 , 7 , 1 6 " 2 0 Reduction of proteinuria and attenuation 
of the loss of glomerular filtration rate (GFR) were 
observed initially with conventional antihypertensive 
therapy, including diuretics and β-blockers, 1 6 , 1 7 the 
exception being monotherapy with diuretics, which 
was suspected to accelerate diabetic nephropathy. 2 1 
Concerning the choice of antihypertensive agents, 
a new argument was introduced by some studies sug­
gesting disparate renal protective effects of different 
antihypertensive drugs in diabetic animals ' 2 5 and 
humans. 2 6 In an attempt to resolve the controversy 
around this possibility, we reported a meta-analysis 
of published studies in diabetics with microalbumin­
uria or overt proteinuria treated with conventional 
agents, angiotensin-converting enzyme (ACE) inhib­
itors, or C a 2 + antagonists. 2 7 , 2 8 Here, we present an 
updated meta-analysis of treatment-effects concern­
ing not only proteinuria but also GFR. 
METHODS 
Studies and Experimental Groups The literature 
was screened for clinical trials using any antihyper­
tensive agents in diabetic patients. The search was 
performed using MEDLINE and publications and ab­
stracts of recent major congresses. Studies fulfilling 
the following criteria were included in our previous 
report 2 8 and the present analysis: 1) diabetic patients 
receiving conventional antihypertensive drugs (di­
uretics and/or β-blockers and sometimes also hydral-
azine-type vasodilators) or a monotherapy with ACE 
inhibitors or C a 2 + antagonists, 2) measurements of 
albuminuria or total proteinuria and BP before and 
after therapy lasting > 4 weeks, and 3) pretreatment 
albuminuria (proteinuria) > 3 0 mg/day. The following 
exclusion criteria were applied: 1) combination ther­
apy if patients were on ACE inhibitors or C a 2 + an­
tagonists, 2) normal albumin excretion ( < 3 0 mg/day) 
at the beginning of the study, 3) studies lasting < 4 
weeks, and 4) repetitive reports of partly similar pa­
tient groups (from such series, only the most complete 
report with the largest population was included). 
Because the literature so far contains only a few 
double-blinded studies with a parallel placebo control 
group, this analysis could not be done without inclu­
sion of studies that were uncontrolled but fulfilled all 
of the above mentioned criteria. The following data 
were extracted: information on the type and known 
duration of diabetes; number, mean age, and gender 
of patients; duration of active drug treatment; and 
pre- and posttreatment mean values for urinary albu­
min or total protein excretion, BP, and, if reported, 
GFR estimated by inulin, 1 2 5 I-iothalamate, 5 1 C r -
EDTA, 9 9Tc-DTPA, or 24 h-creatinine clearance. 
Statistical Analysis Study end-points were mean 
arterial BP (mm Hg), GFR (mL/min), and urine pro­
tein excretion defined as either albumin or total pro­
tein excretion ^g/min) . Each end-point consisted of 
two values, one at baseline and one after treatment. 
The relative change of the mean (expressed as per­
centage) between these two timepoints was used for 
analysis. In studies with more than one measurement 
after > 4 weeks of treatment duration, the mean value 
was used. 
Statistical analyses were performed using the soft­
ware package of the SAS Institute (Cary, N C ) . 2 9 Ef-
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fects of antihypertensive therapy on urinary albumin 
or protein excretion, mean BP and GFR were calcu­
lated separately for the different classes of agents. 
Treatment effects were weighted by the number of 
patients in each report in relation to the total number 
of patients and number of reports, and mean values 
and 95% confidence intervals (CI) were calculated. 
Differences between the drug-specific classes were 
tested by analysis of variance and were considered 
significant at Ρ < .05 (two-tailed). Multiple regression 
analysis was applied to determine the influence of 
different independent explanatory variables on study 
end points. Type of medication, initial mean BP, ini­
tial urinary albumin or total protein excretion, type of 
diabetes, duration of the study, and number of pa­
tients investigated were considered as independent 
variables. Forward stepwise regression analysis was 
then performed for each treatment group to identify 
which of the independent variables could be explan­
atory for renal effects. Linear regression analysis was 
carried out using change in mean BP, initial mean BP, 
or initial level of albumin or total protein excretion as 
independent variables and change in urinary albumin 
or total protein excretion and change in GFR, as de­
pendent variables. ANOVA was used to compare the 
differences between the agent-specific groups. F-test 
for equal variances in groups with different sample 
sizes did not reveal any violation of the ANOVA as­
sumptions. The statistical difference of the final re­
gression lines were calculated using a model as de­
scribed by Kleinbaum et a l . 3 0 
RESULTS 
Study Characteristics From 260 publications identi­
fied by the literature search 93 fulfilled the inclusion 
criteria and contained 115 treatment groups. Of 
these, 68 treatment groups were allocated to the ACE 
inhibitor ca tegory 2 8 ' 3 1 " 6 2 , 27 28,38,45,53,57,61,63 t Q t h e 
C a 2 + antagonist category, and 21 28 ,42 ,58 ,61 ,64^9 t Q t h e 
conventional (diuretic and/or β-blocker) treatment 
category (Table 1). 
The analysis included a total of 1610 patients with a 
mean age of 46 ± 11 years (mean ± SEM) in all re­
ports. The mean proportion of men in all reports was 
62 ± 23%. The reported type of diabetes was 39% for 
type I, 37% type II, in 11% a mixture of both types, 
and in 13% of the reports no indication was given. 
Age, gender, type of diabetes, and mean duration of 
therapy did not differ significantly between the treat­
ment groups. 
Urine Albumin or Total Protein Excretion Albumi­
nuria or total proteinuria tended to decrease on av­
erage more on ACE inhibitors than on conventional 
therapy or all C a 2 + antagonists together, but the dif­
ference did not reach statistical significance. More­
over, albuminuria or total proteinuria tended to in­
crease on nifedipine, despite similar average BP re­
ductions (Table 1). This differs significantly (P < .05) 
from changes on conventional therapy, ACE inhibi­
tors, or C a 2 + antagonists other than nifedipine. 
ACE inhibitor-induced changes in albuminuria or 
proteinuria correlated significantly with decreases in 
BP (r = 0.77, Ρ < .00001; Figure 1). The decrease in 
albuminuria or proteinuria averaged - 2 8 % at zero 
BP change, and varied 1.5% for each percent BP 
change. The slope and intercept describing reduction 
of albuminuria as a function of the decrement in BP 
differs between ACE inhibitors and the other antihy­
pertensive therapies (P < .05). The effects of struc­
turally different ACE inhibitors were similar (data not 
shown). The duration of therapy with ACE inhibitors 
did not affect the magnitude of change in proteinuria. 
On therapy with conventional antihypertensive 
agents, changes in albuminuria-proteinuria and BP 
were also correlated (r = 0.61, Ρ < .005, slope 4.0, 
y-intercept 15.9; Figure 2). However, albumin or total 
protein excretion started to decrease only at a BP 
reduction of > 5 % , and the slope was steeper 
(4% change in albuminuria-proteinuria per percent 
BP change) than on ACE inhibitors. The regression 
line differed from the ACE inhibitors regression line 
but not in comparison with the regression line on 
treatment with C a 2 + antagonists other than nifed­
ipine. 
TABLE 1. ANTIPROTEINURIC ACTION OF ANTIHYPERTENSIVE DRUGS IN DIABETICS: META-ANALYSIS 
Average Changes (%) 
Type of 
Therapy 
Ν 
Reports Subjects 
Mean Study 
Duration (mo) 
Mean 
Systemic BP 
Urinary Albumin 
or Protein 
Diuretics and/or β-blockers 21 258 15.5 (9/22) - 1 0 (-12/ - 8) 
ACE inhibitors 68 1061 8.2 (6/11) - 1 2 ( - 1 9 / - 5 ) 
C a 2 + antagonists 
all 27 398 5.4 (3/7) - 1 2 ( -15 / -10 ) 
Nifedipine 12 166 5.9 (3/9) - 1 3 ( - 1 7 / - 9 ) 
all except nifedipine 15 232 5.0 (2/8) - 1 1 ( - 1 4 / - 7) 
- 2 3 ( - 3 5 / - 1 1 ) 
- 4 5 ( - 0 4 / - 2 5 ) —J 
- 1 7 ( - 3 3 / - 2 ) I 
+ 5 ( -21 / + 31) — 
- 3 5 ( - 4 7 / - 2 4 ) ^ T 
Mean (95% confidence interval). 
*P < .05. 
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FIGURE 1. Percentage changes in albuminuria-proteinuria as 
related to blood pressure changes in diabetics on angiotensin-
converting enzyme inhibitors. 
Although the distribution of data points did not 
differ obviously between reports using diuretic 
monotherapy, β-blocker monotherapy, or their com­
bination, differences between their monotherapy or 
combination are not excluded as the limited number 
of reports precludes a separate analysis. 
In the treatment group including all C a 2 + antago­
nists, changes in albuminuria or proteinuria were un­
related to BP changes (Figure 3). Further stratification 
of this group into two subgroups treated with either 
nifedipine or C a 2 + antagonists other than nifedipine 
(including verapamil, diltiazem, and the dihydropy­
ridines nicardipine, nitrendipine, and isradipine), re­
vealed a significant relationship between change in 
BP and albumin or total protein excretion in the latter 
(r = 0.55, Ρ < .05, slope 2.6, y-intercept - 7 . 9 ; Figure 
3), but not in the nifedipine subgroup. In 4 of 13 
s t u d i e s 5 5 , 6 0 , 7 0 , 7 1 with nifedipine, proteinuria was re­
ported to be increased despite of a decrease in BP. 
Choosing another subgroup assignment, namely 
Change in 24 h-Urine 
Albumin or Protein, Δ% 
100 Ν = 21 r = 0.61 
Ρ < 0.005 
-30 -25 -20 -15 -10 -5 0 5 
Change in Mean Blood Pressure, Δ% 
FIGURE 2. Percentage changes in albuminuria-proteinuria as 
related to blood pressure changes in diabetics on "conventional" 
drugs. 
-30 -25 -20 -15 -10 -5 0 
Change in Mean Blood Pressure, Δ% 
Symbol Drug Ν r P< 
• Ca-Antagonist 15 0.78 0.001 
Ο Nifedipine 12 0.14 n.s. 
FIGURE 3. Percentage changes in albuminuria-proteinuria as 
related to blood pressure changes in diabetic on Ca2 + antagonists 
(Ca-Antagonist) and nifedipine. 
C a 2 + antagonists of the dihydropirine type versus 
nondihydropyridines revealed no statistical relation­
ship between the reduction in albuminuria and de­
crease in mean BP. 
Glomerular Filtration Rate Seventy reports contained 
data on G F R 2 0 , 2 1 , 2 8 , 3 2 , 3 6 , 3 8 , 3 9 , 4 1 ^ 3 , 4 6 , 4 9 , 5 1 , 5 2 , 5 4 " 5 6 , 6 3 , 6 7 , 6 9 , 7 0 
(Table 2). The latter was measured by the clearances 
of inulin, 9 9Tc-DTPA, 1 2 5I-iothalamate, or 5 1 Cr-EDTA 
in 53 studies and was estimated by the clearance of 
creatinine in 17 studies. 
During the observation period, GFR on average 
was unchanged on ACE inhibitors and tended to de­
crease minimally on conventional therapy or all 
C a 2 + - a n t a g o n i s t s analyzed together. Although 
changes did not reach statistical significance, this ten­
dency was associated with nifedipine treatment (Ta­
ble 2). 
ACE inhibitor-induced changes in GFR correlated 
inversely with changes in mean BP, therefore GFR 
tended to increase with progressive BP reduction 
(Figure 4). On C a 2 + antagonists or conventional 
therapy, variations in GFR were unrelated to changes 
in BP. 
DISCUSSION 
These findings demonstrate a predominance of drug-
specific over systemic BP-dependent mechanisms in 
the antiproteinuric action of ACE inhibitors in diabetic 
patients. In contrast, as the example of nifedipine il­
lustrates, drug-specific intrarenal effects may antag­
onize a BP-dependent antiproteinuric action and 
even counteract the effect of lowering systemic BP. 
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TABLE 2. EFFECTS OF ANTIHYPERTENSIVE DRUGS ON GLOMERULAR FILTRATION IN DIABETICS: 
META-ANALYSIS 
Average Changes (%) 
Type of Ν Mean Study Mean Glomerular 
Therapy Reports Subjects Duration (mo) Systemic BP Filtration Rate* 
Diuretics and/or β-blockers 16 190 16.4 (8/25) - 1 1 ( - 1 3 / - 8 ) - 1 . 9 ( - 1 0 / - 1 ) 
ACE inhibitors 38 604 6.8 (5/9) - 1 6 ( - 2 8 / - 4 ) -0 .01 (-6/4-6) 
C a 2 + antagonists 
All 16 205 6.6 (3/16) - 1 4 ( -17 / -10 ) - 2 . 2 ( - 1 1 / + 7) 
Nifedipine 8 107 7.4 (2/12) - 1 4 ( - 2 0 / - 9 ) - 9 . 9 ( -25/ + 5) 
all except nifedipine 8 98 5.8 (1/11) - 1 3 ( - 1 7 / - 8 ) + 5.6 ( -4 / + 15) 
Mean (95% confidence interval). 
*51Cr-EDTA, Inulin, 125I-iothalamate, "Tc-DTPA or creatinine clearance. 
With progressive lowering of BP, the antialbuminuric 
effect increases less on ACE inhibitors than on con­
ventional antihypertensive therapy or C a 2 + antago­
nists other than nifedipine. It is obvious from Figure 
5 that a difference or no difference between ACE in­
hibitors and alternative antihypertensive treatments 
may occur depending on how markedly BP has been 
lowered. This explains some controversies in the lit­
erature. 
This meta-analysis also reveals that with progres­
sive BP reduction GFR tended to increase on ACE 
inhibitors, but not on conventional antihypertensive 
therapy or Ca 2 + antagonists. This complements the 
disparate renal profile of different antihypertensive 
agents in diabetics with incipient or overt nephropathy. 
Renal effects of antihypertensive agents are medi-
-30 -20 -10 
Δ % Mean Blood Pressure 
S y m b o l D r u g Ν r P< 
• ACE Inhibitor 39 -0.55 0.0005 
X Conventional 16 0.12 n.s. 
• Ca-Antagonist 8 0.43 n.s. 
Ο Nifedipine 8 0.46 n.s. 
FIGURE 4. Percentage changes in glomerular filtration rate 
(GFR) as related to blood pressure changes in diabetics on anti­
hypertensive drugs. 
ated, at least in part, by direct intrarenal actions. In­
trarenal hemodynamics, tubular function, or mesan­
gial cell metabolism may be modified. 
ACE inhibitors block the generation of angiotensin 
II, a potent inducer of intrarenal vasoconstriction. 
Furthermore, ACE inhibitors increase levels of va­
sodilatory prostaglandins PGI2 and PGE2 through in­
hibition of kininase II, an enzyme identical to A C E . 7 2 
Therefore, these agents dilate both afferent and effer­
ent arterioles and consequently reduce glomerular 
capillary pressure. Because they dilate preferentially 
efferent over afferent glomerular arterioles, 7 3 a fall in 
systemic BP will cause a greater, decrease of glomer­
ular capillary pressure. ACE inhibition may also re­
duce angiotensin II-induced mesangial contraction 
and, thereby, increase the glomerular filtration sur­
face. More controversy exists with regard to the in­
trarenal hemodynamic effects of C a 2 + antagonists. 
Although their ability to induce substantial afferent 
arteriolar vasodilatation is well demonstrated, their 
Change in 24 h-Urine 
Albumin or Protein, Δ% 
-20 
-40 
-60 
-80 
Conventional 
Ca-Antagonist 
ACE Inhibitor 
-30 -20 -10 0 
Change in Mean Blood Pressure, Δ% 
FIGURE 5. Percentage changes in albuminuria-proteinuria as 
related to blood pressure changes in diabetics on antihypertensive 
drugs. 
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effect on efferent arteriolar resistance remains contro­
versial. In animal and human studies verapamil and 
diltiazem have been noted to lower glomerular cap­
illary p r e s s u r e . 1 9 , 7 3 ' 7 4 The majority of studies investi­
gating the renal hemodynamics of dihydropyridines 
showed no effect of nifedipine on efferent arteriolar 
resistance. 7 5 Therefore, a beneficial influence of low­
ered systemic BP on glomerular pressure may be an­
tagonized by preferential afferent over efferent glo­
merular vasodilatation, which occurs with certain 
Ca 2 + antagonists. 7 6 
Considering nonhemodynamic actions, certain 
C a 2 + antagonists may tend to inhibit renal hypertro­
phy associated with diabetes. 7 7 Both C a 2 + antago­
nists and ACE inhibitors may influence beneficially 
the metabolism of mesangial ce l ls , 7 7 , 7 8 whereas ACE 
inhibitors also may decrease glomerular permeability 
for proteins , 2 5 , 7 9 probably by affecting charge and 
size selectivity of the glomerular capillary barrier in 
humans. 8 0 ACE inhibitors also limited the develop­
ment of glomerular structural lesions as well as tubu­
lar interstitial damage. The biological mechanisms 
that could prevent these lesions are not completely 
understood, but studies in mesangial cells suggested 
the involvement of nitric oxide, 8 1 which itself could 
be influenced by ACE inhibitors by inhibition of local 
bradykinin degradation. 2 4 , 8 1 On the other hand, the 
lack of effect of nifedipine on albumin excretion may 
depend, perhaps in part, on proximal tubular inter­
actions. 4 6 Nifedipine caused a marked reduction in 
fractional lithium reabsorption and a corresponding 
increase in lithium clearance. 8 2 32-Microglobulin, a 
freely filterable protein and, therefore, also used as a 
marker of proximal tubular function, 8 3 was signifi­
cantly increased during nifedipine treatment com­
pared with lisinopril therapy. 4 6 , 8 4 The inhibitory ef­
fect of nifedipine on several proximal tubular func­
tion markers is consistent with the possibility that it 
might also inhibit proximal tubular albumin reabsorp­
tion, thereby promoting albuminuria despite its sys­
temic antihypertensive effect. 
As ACE inhibitors exert a specific antiproteinuric 
effect even without a change in systemic BP (Figure 
5), they are superior to other agents in treating mi­
croalbuminuria or overt proteinuria in initially nor­
motensive or mildly hypertensive diabetic patients. 
On the other hand, when systemic BP can be lowered 
by 20%, as it is desirable and achievable in more se­
verely hypertensive patients, ACE inhibitors, con­
ventional therapy, and several C a 2 + antagonists all 
have a distinct antiproteinuric action. 
Nevertheless, effects of agents on the kidney can­
not be the sole criterion in selecting an antihyperten­
sive drug for diabetic patients. The influence of drugs 
on serum lipid levels and glucose and potassium me­
tabolism as well as their ability to reduce left ventric­
ular hypertrophy should also be considered. ' Al­
though thiazide or loop diuretics and β-blockers can 
have an adverse metabolic influence, ACE inhibitors 
may improve slightly insulin res i s tance 8 6 and, 
thereby, tend to improve glucose control in NIDDM 
patients. 8 7 ACE inhibitors and C a 2 + antagonsits also 
are neutral with regard to serum lipoproteins. 
Most important, the ultimate goal of therapy is to 
improve life prognosis. In essential hypertension, BP-
lowering drug treatment based on diuretics in high 
dosage satisfactorily reduced cerebrovascular but not 
coronary complications or sudden death. 8 8 However, 
in diabetic patients a beneficial influence of conven­
tional antihypertensive therapy on prognosis has not 
been demonstrated. In fact, based on retrospective 
analyses, different investigators noted an excess mor­
tality of diuretic-treated diabetic pat ients . 8 9 , 9 0 Evalu­
ating the prognostic outcome in diabetic patients with 
severe retinopathy, Warram et a l 9 0 found a 3.8 times 
higher cardiovascular mortality rate in patients 
treated with diuretics alone than in diabetic patients 
with untreated hypertension; the cardiovascular mor­
tality rate was increased in diuretic-treated diabetic 
subjects with or without clinical proteinuria. On the 
other hand, it was calculated that in the very high-
risk group of patients with diabetic nephropathy, ef­
fective BP control might possibly reduce 10-year mor­
tality rates from 65 to 2 0 % . 9 1 In the first large pro­
spective trial on prognosis, long-term ACE inhibition 
with captopril in overt diabetic nephropathy has just 
been reported to reduce markedly their combined 
risk of mortality or needing dialysis or transplanta­
tion. 9 2 These data underline the achievable long-term 
benefits of effective drug treatment on the prognosis 
in a special high-risk group of patients. 
Based on the available data, ACE inhibitors have 
emerged as the preferred first-line drugs in the treat­
ment of diabetic patients with nephropathy. Further­
more, ACE inhibitors, C a 2 + antagonists other than 
nifedipine and, if necessary, the diuretic indapamide 
are effective antihypertensive drugs that do not affect 
adversely metabolic profile of diabetic patients. 8 6 
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